Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity

Annals of Human Genetics

Volumn 72, Issue 1, 2008, Pages 72-81

  Sanghera, Dharambir K ^a,c   Manzi, Susan ^b   Minster, Ryan L ^a   Shaw, Penny ^b   Kao, Amy ^b   Bontempo, Franklin ^b   Kamboh, M Ilyas ^a  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Paraoxonase activity; Paraoxonase 3; Polymorphisms; SLE

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 3; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; ALLELES; ANTIBODIES, ANTIPHOSPHOLIPID; ARYLDIALKYLPHOSPHATASE; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; ESTERASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; INFLAMMATION; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; RISK FACTORS; UNITED STATES; VARIATION (GENETICS);

EID: 37849049575     PISSN: 00034800     EISSN: 14691809     Source Type: Journal    
DOI: 10.1111/j.1469-1809.2007.00400.x     Document Type: Article

References (37)

1. Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I. & Tawfik, D. S. (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A 101, 482-7.
2. Audikovszky, M., Pados, G., Seres, I., Harangi, M., Fulop, P., Katona, E., Illyes, L., Winkler, G., Katona, E. M. & Paragh, G. (2007) Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis 17, 268-73.
3. Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C. & La Du, B. (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18, 1617-24.
4. Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H. & Hayek, T. (2004) Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 23, 423-33.
5. Boemi, M., Leviev, I., Sirolla, C., Pieri, C., Marra, M. & James, R. W. (2001) Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155, 229-35.
6. Costa, L. G., Cole, T. B., Jarvik, G. P. & Furlong, C. E. (2003) Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54, 371-92.
7. Delgado Alves, J., Ames, P. R., Donohue, S., Stanyer, L., Nourooz-Zadeh, J., Ravirajan, C. & Isenberg, D. A. (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46, 2686-94.
8. Draganov, D. I. & La Du, B. N. (2004) Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch Pharmacol 369, 78-88.
9. Draganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S. & La Du, B. N. (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275, 33435-42.
10. Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R. & La Du, B. N. (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46, 1239-47.
11. Durrington, P. N., Mackness, B. & Mackness, M. I. (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21, 473-80.
12. Esdaile, J. M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R., Cote, R., Grover, S. A., Fortin, P. R., Clarke, A. E. & Senecal, J. L. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44, 2331-7.
13. Hayem, G., Nicaise-Roland, P., Palazzo, E., de Bandt, M., Tubach, F., Weber, M. & Meyer, O. (2001) Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 10, 346-51.
14. Hochberg, M. C. (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40, 1725.
15. Jakubowski, H. (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275, 3957-62.
16. Koch, M., Hering, S., Barth, C., Ehren, M., Enderle, M. D. & Pfohl, M. (2001) Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease: Interaction with type 2 diabetes. Exp Clin Endocrinol Diabetes 109, 141-5.
17. Lee, A. B., Godfrey, T., Rowley, K. G., Karschimkus, C. S., Dragicevic, G., Romas, E., Clemens, L., Wilson, A. M., Nikpour, M., Prior, D. L., Best, J. D. & Jenkins, A. J. (2006) Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 36, 237-43.
18. Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B., Miller, J. E., Boulton, A. J. & Durrington, P. N. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139, 341-9.
19. Mackness, M. I., Arrol, S. & Durrington, P. N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286, 152-4.
20. Mackness, M. I., Peuchant, E., Dumon, M. F., Walker, C. H. & Clerc, M. (1989) Absence of "A"-esterase activity in the serum of a patient with Tangier disease. Clin Biochem 22, 475-8.
21. Mackness, M. I., Walker, C. H. & Carlson, L. A. (1987) Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem 33, 587-8.
22. McElveen, J., Mackness, M. I., Colley, C. M., Peard, T., Warner, S. & Walker, C. H. (1986) Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32, 671-3.
23. Mochizuki, H., Scherer, S. W., Xi, T., Nickle, D. C., Majer, M., Huizenga, J. J., Tsui, L. C. & Prochazka, M. (1998) Human PON2 gene at 7q21.3: Cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213, 149-57.
24. Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M. & Reddy, S. T. (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276, 44444-9.
25. Primo-Parmo, S. L., Sorenson, R. C., Teiber, J. & La Du, B. N. (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33, 498-507.
26. Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gangopadhyay, A., Shih, D. M., Lusis, A. J., Navab, M. & Fogelman, A. M. (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21, 542-7.
27. Roest, M., van Himbergen, T. M., Barendrecht, A. B., Peeters, P. H., van der Schouw, Y. T. & Voorbij, H. A. (2007) Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 37, 187-96.
28. Selzer, F., Sutton-Tyrrell, K., Fitzgerald, S., Tracy, R., Kuller, L. & Manzi, S. (2001) Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37, 1075-82.
29. Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M. & Lusis, A. J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-7.
30. Shih, D. M., Xia, Y. R., Wang, X. P., Wang, S. S., Bourquard, N., Fogelman, A. M., Lusis, A. J. & Reddy, S. T. (2007) Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 100, 1200-7.
31. Sinnwell, J. P. & Schaid, D. J. (2005) Haplostats: Statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfm.
32. Svenungsson, E., Jensen-Urstad, K., Heimburger, M., Silveira, A., Hamsten, A., de Faire, U., Witztum, J. L. & Frostegard, J. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887-93.
33. Tan, E. M., Fritzler, M. J., McDougal, J. S., McDuffie, F. C., Nakamura, R. M., Reichlin, M., Reimer, C. B., Sharp, G. C., Schur, P. H., Wilson, M. R. & Winchester, R. J. (1982) Reference sera for antinuclear antibodies. I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La. Arthritis Rheum 25, 1003-5.
34. Tripi, L. M., Manzi, S., Chen, Q., Kenney, M., Shaw, P., Kao, A., Bontempo, F., Kammerer, C. & Kamboh, M. I. (2006) Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 54, 1928-39.
35. Vaarala, O., Alfthan, G., Jauhiainen, M., Leirisalo-Repo, M., Aho, K. & Palosuo, T. (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341, 923-5.
36. Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M. & Navab, M. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96, 2882-91.
37. Zhao, J. H., Curtis, D. & Sham, P. C. (2000) Model-free analysis and permutation tests for allelic associations. Hum Hered 50, 133-9.